NVS
NovartisDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Execution beats on core portfolio and successful launches/approvals push revenue and margin upside; cost discipline and share buybacks support multiple expansion toward the analyst high (~$175) as investors re-rate growth optionality.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
Accelerated biosimilar/generic erosion in key markets
Momentum
27
Value
64
Sentiment
42
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $144.40 · Bull $175.00 · Bear $109.51
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-02-04 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $152.90
Why
Momentum27 · Δ7d -27.4
Value64 · Δ7d -0.2
Sentiment42 · Δ7d -0.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
27
26% active weight
Current posture
7d trendSoftening
Δ7d
-27.4
Δ21d
-6.5
Value
64
39% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.1
Sentiment
42
34% active weight
Current posture
7d trendFlat
Δ7d
-0.4
Δ21d
+1.1
Why this grade
Composite grade D. Momentum 27.2 / Value 64.4 / Sentiment 41.6
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$285.51B
Beta
0.78
Shares Out
1.83B
P/E (TTM)
18.7
P/S (TTM)
5.16
P/FCF (TTM)
31.31
Rev YoY
-0.6%
EPS YoY
-9.5%
Gross Margin
+74.6%
Op Margin
+31.0%
Net Debt
$23.79B
Current Ratio
0.85
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology